SANES

10.429

-1.21%↓

BBVA

18.95

-0.01%↓

CABK

10.812

-1.19%↓

INGA

25.52

-0.87%↓

NDA.FI

15.57

-1.89%↓

SANES

10.429

-1.21%↓

BBVA

18.95

-0.01%↓

CABK

10.812

-1.19%↓

INGA

25.52

-0.87%↓

NDA.FI

15.57

-1.89%↓

SANES

10.429

-1.21%↓

BBVA

18.95

-0.01%↓

CABK

10.812

-1.19%↓

INGA

25.52

-0.87%↓

NDA.FI

15.57

-1.89%↓

SANES

10.429

-1.21%↓

BBVA

18.95

-0.01%↓

CABK

10.812

-1.19%↓

INGA

25.52

-0.87%↓

NDA.FI

15.57

-1.89%↓

SANES

10.429

-1.21%↓

BBVA

18.95

-0.01%↓

CABK

10.812

-1.19%↓

INGA

25.52

-0.87%↓

NDA.FI

15.57

-1.89%↓

Home・Akcijų sąrašas・Ipsen SA.

Ipsen SA.

Uždarymo kaina

SektoriusFinansų sektorius

166.4 -1.45

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

165.2

Max

168.9

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-225M 110M
Pardavimai	36M 1.9B
P/E Sektoriaus vid.	31.238 57.018
Dividendų pajamingumas	0.84
Pelno marža	5.899
Darbuotojai	5,535
EBITDA	-171M 466M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-16.71% downside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	0.84% 4.62%
Kitas uždarbis	2026-07-30

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2.4B 14B
Ankstesnė atidarymo kaina	167.85
Ankstesnė uždarymo kaina	166.4

Naujienos nuotaikos

By Acuity

19%

81%

41 / 439 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

99.85 / 104 Palaikymas ir pasipriešinimas

Ipsen SA. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-07 23:58; UTC

Uždarbis

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

2026-05-07 22:57; UTC

Uždarbis

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

2026-05-07 23:52; UTC

Uždarbis

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

2026-05-07 23:45; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026-05-07 23:39; UTC

Rinkos pokalbiai

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

2026-05-07 23:28; UTC

Rinkos pokalbiai

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

2026-05-07 23:11; UTC

Uždarbis

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

2026-05-07 23:06; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

2026-05-07 23:05; UTC

Uždarbis

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

2026-05-07 23:04; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

2026-05-07 23:03; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

2026-05-07 23:03; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

2026-05-07 23:02; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

2026-05-07 23:00; UTC

Rinkos pokalbiai

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

2026-05-07 22:45; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-07 22:45; UTC

Rinkos pokalbiai

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

2026-05-07 22:42; UTC

Uždarbis

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

2026-05-07 22:33; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

2026-05-07 22:32; UTC

Uždarbis

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

2026-05-07 22:31; UTC

Uždarbis

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

2026-05-07 22:31; UTC

Uždarbis

Macquarie: 68% of FY Income From International >MQG.AU

2026-05-07 22:30; UTC

Uždarbis

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

2026-05-07 22:30; UTC

Uždarbis

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

2026-05-07 22:29; UTC

Uždarbis

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

2026-05-07 22:28; UTC

Uždarbis

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

2026-05-07 22:28; UTC

Uždarbis

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

2026-05-07 22:27; UTC

Uždarbis

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

2026-05-07 22:27; UTC

Uždarbis

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

2026-05-07 22:26; UTC

Uždarbis

Macquarie to End Share Buyback Extended in November>MQG.AU

2026-05-07 22:25; UTC

Uždarbis

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Akcijų palyginimas

Kainos pokytis

Ipsen SA. Prognozė

Kainos tikslas

By TipRanks

-16.71% į apačią

12 mėnesių prognozė

Vidutinis 144 EUR -16.71%

Aukščiausias 170 EUR

Žemiausias 130 EUR

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ipsen SA. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Ipsen SA. akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

99.85 / 104Palaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Rinkos nuotaikos

By Acuity

41 / 439 reitingas Finansų sektorius

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.